Blood Cancer Journal

Article	Citations
CAR-T cell therapy: current limitations and potential strategies	1213
Acute myeloid leukemia: current progress and future directions	391
CAR T-cell therapy in multiple myeloma: more room for improvement	112
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies	106
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies	106
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment	101
Acute promyelocytic leukemia current treatment algorithms	98
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia	96
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm	95
Extramedullary disease in multiple myeloma: a systematic literature review	93
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report	93
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage	87
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia	85
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm	83
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma	81
Chromosome 1q21 abnormalities in multiple myeloma	78
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study	70
Global burden of hematologic malignancies and evolution patterns over the past 30 years	65
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up	62
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia	62
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)	62
Core binding factor acute myelogenous leukemia-2021 treatment algorithm	61
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life	61
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis	61
Genetic and epigenetic determinants of diffuse large B-cell lymphoma	58

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis	58
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma	54
Management of chronic myeloid leukemia in 2023 – common ground and common sense	54
Extramedullary disease in multiple myeloma	53
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab	53
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy	52
Diffuse large B-cell lymphoma: new targets and novel therapies	50
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis	50
A simple additive staging system for newly diagnosed multiple myeloma	47
Comprehensive Review of AL amyloidosis: some practical recommendations	47
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel	46
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia	45
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)	45
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results	45
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantati	43
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	42
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden	41
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study	41
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment	41
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis	41
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements	39
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy	39
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse	38
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study	38
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML	38
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions	35
A clinical perspective on plasma cell leukemia; current status and future directions	35
Differentiation therapy for myeloid malignancies: beyond cytotoxicity	35
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies	34
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo	34
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma	33
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine	33
Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing	33
Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia	33
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience	32
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial	32
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma	32
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia	31
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab	31
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma	31
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study	31
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program	31
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia	31
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma	31
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07	31
Mutations and thrombosis in essential thrombocythemia	31
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma	31
Financial toxicity in hematological malignancies: a systematic review	30
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021	30
Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center	29

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation	29
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice	29
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies	29
Impact of COVID-19 in patients with multiple myeloma based on a global data network	29
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review	28
Smoldering multiple myeloma current treatment algorithms	28
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication	28
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee	27
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy	27
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points	26
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study	26
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019	26
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients	26
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells	26
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	25
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19	25
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression	25
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients	24
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib	24
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML	24
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients	24
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies	24
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018	24
Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities	23
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review	23
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update	23
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients	23
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia	23
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera	22
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	22
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis	22
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib	22
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma	22
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	21
Cutaneous manifestations of monoclonal gammopathy	21
Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	21
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy	21
Infectious complications of bispecific antibody therapy in patients with multiple myeloma	21
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation	21
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)	21
Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia	21
Chronic lymphocytic leukemia treatment algorithm 2022	21
Genomic characterization of functional high-risk multiple myeloma patients	20
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients	20
Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism	19
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia	19
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia	19
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients	19
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins	19
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement	19
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL	18
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group	18
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma	18
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma	18
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	18
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota	17
HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias	17
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	17
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma	17
Preclinical development of CD126 CAR-T cells with broad antitumor activity	17
Therapeutic targeting of the inflammasome in myeloid malignancies	17
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins	17
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia	16
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients	16
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry	16
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma	16
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation	16
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome	16
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia	16
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	16
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation	15
Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma	15
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial	15
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT	15
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants	15
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis	15
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial	15
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients	15
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia	15
Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria	15

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm	15
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors	15
Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes	14
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma	14
Management of patients with lower-risk myelodysplastic syndromes	14
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation	14
Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany	14
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study	14
Resistance to targeted therapies: delving into FLT3 and IDH	14
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment	14
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome	14
4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas	14
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis	14
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action	14
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies	14
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia	14
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis	13
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms	13
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review	13
Multiple myeloma with acute light chain cast nephropathy	13
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1	13
Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies	13
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study	13
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	13
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML	13
Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?	12
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases	12
One thousand patients with essential thrombocythemia: the Mayo Clinic experience	12
Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis	12
Lifestyle considerations in multiple myeloma	12
Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma	12
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019	12
Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series	12
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation	12
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma	12
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX	12
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience	12
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression	12
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients	12